Table 2

Patients Eligible for BB Optimization or Ivabradine Treatment, as Identified by ESC Guidelines, With Baseline Characteristics According to Missed Versus Not Missed Indication

VariablesSuitable for BB Optimization
(n = 33)
Suitable for Ivabradine
(n = 25)
Missed
(n = 20)
Not Missed
(n = 13)
p ValueMissed
(n = 15)
Not Missed
(n = 10)
p Value
Age, yrs72 ± 1272 ± 100.9668 ± 1272 ± 130.40
Sex12 (60%)11 (85%)0.1310 (67%)7 (70%)0.86
BMI, kg/m225 (22–30)29 (24–34)0.0528 (25–31)29 (26–31)0.68
NYHA functional class III/IV6 (30%)2 (15%)0.345 (33%)3 (30%)0.86
SBP, mm Hg128 ± 20139 ± 250.18123 ± 22123 ± 240.99
HR, beat/min77 ± 782 ± 100.0776 ± 486 ± 150.03
LVEF, %30 ± 429 ± 50.6227 ± 728 ± 70.66
NT-proBNP, ng/l1,635 (541–3,970)1,297 (603–3,236)0.631,374 (712–2,156)2,303 (1,163–5,750)0.29
eGFR, ml/min48 (30–73)51 (28–63)0.8751 (40–71)35 (21–48)0.08
Sinus rhythm20 (100%)13 (100%)N/A15 (100%)10 (100%)N/A
BiV pacing5 (25%)2 (15%)0.513 (20%)4 (40%)0.28
IHD13 (65%)12 (92%)0.0311 (73%)8 (80%)0.71
ACE-I/ARB20 (100%)12 (92%)0.2113 (87%)10 (100%)0.23
BB19 (95%)13 (100%)0.4114 (93%)6 (60%)0.04
BB ≥50%9 (45%)6 (46%)0.9510 (67%)5 (50%)0.41
MRA11 (55%)11 (85%)0.0812 (80%)4 (40%)0.04

Values are mean ± SD, n (%), or median (interquartile range). p Values represent differences between missed and not missed groups.

ESC = European Society of Cardiology; other abbreviations as in Table 1.